Bioavailability of Dabigatran Formulations in Healthy Males

Phase 1, randomised, open-label trial of dabigatran etexilate oral solution in venous thromboembolism (VTE) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran at 60 hours and Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran at 60 hours. Started Jan 2014; status: completed.